Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents

Li Min Huang, Luan Yin Chang, Haiwen Tang, Hans L. Bock, Chun Yi Lu, Fu Yuan Huang, Tzou Yien Lin, Chin Yun Lee

研究成果: 雜誌貢獻文章

19 引文 (Scopus)

摘要

Purpose: Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix™, GlaxoSmithKline Biologicals' reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine. Methods: Healthy Taiwanese children and adolescents aged 6-8 years and 15-20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix™. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded. Results: A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between 89.0-100%. There were no serious adverse events reported during the study period. Conclusions: The results of this study suggest that Boostrix™ may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine.
原文英語
期刊Journal of Adolescent Health
37
發行號6
DOIs
出版狀態已發佈 - 十二月 2005
對外發佈Yes

指紋

Diphtheria-Tetanus-acellular Pertussis Vaccines
Diphtheria-Tetanus-Pertussis Vaccine
Antigens
Vaccination
Vaccines
Whooping Cough
Immunosorbent Techniques
Diphtheria Toxoid
Secondary Immunization
Bordetella pertussis
Tetanus Toxoid
Antibodies
Immunity
Healthy Volunteers
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Serum
Population
Boostrix

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

引用此文

Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents. / Huang, Li Min; Chang, Luan Yin; Tang, Haiwen; Bock, Hans L.; Lu, Chun Yi; Huang, Fu Yuan; Lin, Tzou Yien; Lee, Chin Yun.

於: Journal of Adolescent Health, 卷 37, 編號 6, 12.2005.

研究成果: 雜誌貢獻文章

Huang, Li Min ; Chang, Luan Yin ; Tang, Haiwen ; Bock, Hans L. ; Lu, Chun Yi ; Huang, Fu Yuan ; Lin, Tzou Yien ; Lee, Chin Yun. / Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents. 於: Journal of Adolescent Health. 2005 ; 卷 37, 編號 6.
@article{9279ae20b44c4e8d87f35ef02844ae88,
title = "Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents",
abstract = "Purpose: Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix™, GlaxoSmithKline Biologicals' reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine. Methods: Healthy Taiwanese children and adolescents aged 6-8 years and 15-20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix™. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded. Results: A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between 89.0-100{\%}. There were no serious adverse events reported during the study period. Conclusions: The results of this study suggest that Boostrix™ may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine.",
keywords = "Adolescents, Booster vaccination, Bordetella pertussis, Reduced-antigen-content dTpa vaccine, Taiwan",
author = "Huang, {Li Min} and Chang, {Luan Yin} and Haiwen Tang and Bock, {Hans L.} and Lu, {Chun Yi} and Huang, {Fu Yuan} and Lin, {Tzou Yien} and Lee, {Chin Yun}",
year = "2005",
month = "12",
doi = "10.1016/j.jadohealth.2005.08.009",
language = "English",
volume = "37",
journal = "Journal of Adolescent Health",
issn = "1054-139X",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents

AU - Huang, Li Min

AU - Chang, Luan Yin

AU - Tang, Haiwen

AU - Bock, Hans L.

AU - Lu, Chun Yi

AU - Huang, Fu Yuan

AU - Lin, Tzou Yien

AU - Lee, Chin Yun

PY - 2005/12

Y1 - 2005/12

N2 - Purpose: Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix™, GlaxoSmithKline Biologicals' reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine. Methods: Healthy Taiwanese children and adolescents aged 6-8 years and 15-20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix™. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded. Results: A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between 89.0-100%. There were no serious adverse events reported during the study period. Conclusions: The results of this study suggest that Boostrix™ may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine.

AB - Purpose: Disease caused by Bordetella pertussis is increasingly being identified among older children and adults in immunized populations, indicating a waning of the vaccine-induced immunity. These findings suggest the need for booster immunization of older children and adults. Modern acellular reduced-antigen-content vaccines have been developed, which can be given as a booster in individuals more than 4 years of age. This study was to assess the immunogenicity and reactogenicity of Boostrix™, GlaxoSmithKline Biologicals' reduced-antigen-content diphtheria-tetanus acellular pertussis (dTpa) vaccine, when administered as a booster in healthy subjects previously primed with DTP vaccine. Methods: Healthy Taiwanese children and adolescents aged 6-8 years and 15-20 years, previously primed with DTP vaccine, were enrolled. All received one dose of Boostrix™. Two blood samples were taken from each of them, one before vaccination and one at 1 month after vaccination. Serum antibodies to diphtheria and tetanus toxoids and immunoglobulin G (IgG) antibodies against the pertussis components PT, FHA and PRN were measured by enzyme-linked immunosorbent assay (ELISA) technique. Adverse reactions following vaccination were recorded. Results: A total of 180 subjects were recruited. The vaccine response rates to the pertussis antigens ranged between 89.0-100%. There were no serious adverse events reported during the study period. Conclusions: The results of this study suggest that Boostrix™ may be safely and effectively administered as a booster dose to children previously primed with DTP vaccine.

KW - Adolescents

KW - Booster vaccination

KW - Bordetella pertussis

KW - Reduced-antigen-content dTpa vaccine

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=27944432479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944432479&partnerID=8YFLogxK

U2 - 10.1016/j.jadohealth.2005.08.009

DO - 10.1016/j.jadohealth.2005.08.009

M3 - Article

C2 - 16310132

AN - SCOPUS:27944432479

VL - 37

JO - Journal of Adolescent Health

JF - Journal of Adolescent Health

SN - 1054-139X

IS - 6

ER -